VIENNA, Austria, October 29, 2015 -

VIENNA, Austria, October 29, 2015 - Miracor Medical Systems GmbH (Miracor) announced today that during this year’s TCT conference in San Francisco, PiCSO has been highlighted in several sessions as offering new hope for Cardioprotection during Percutaneous Coronary Intervention (PCI). TCT (Transcatheter Cardiovascular Therapeutics) is the world's largest educational meeting specializing in interventional cardiovascular medicine and was held by the Cardiovascular Research Foundation (CRF) on October 10th - 16th, 2015 in San Francisco, CA, USA.

Myocardial salvage and the need for cardioprotection for patients with acute myocardial infarction (AMI) was a focus topic, yet again, at this year’s TCT conference.

“Despite recent improvements in the treatment of AMI, including shortened door-to-balloon times and advanced pharmacological strategies, survival has plateaued, and novel strategies are needed to reduce infarct size and improve clinical outcomes, especially in patients with large ST-segment elevation MI (STEMI),” stated Dr. Gregg W. Stone, Professor of Medicine at Columbia University College and Director of Cardiovascular Research and Education at the New York-Presbyterian Hospital Center for Interventional Vascular Therapies, during a symposium on novel strategies in PCI with focus on PiCSO Therapy. “In recent years, many approaches to improve reperfusion success and myocardial salvage have failed. Emerging data suggests that the effective delivery of PICSO improves myocardial perfusion and may reduce infarct size in STEMI patients,” he continued.

PiCSO is applied during the stenting procedure, directly following flow restoration and increases myocardial perfusion and microcirculation, thereby preventing so-called reperfusion injury, damage to the myocardium caused by the stenting procedure itself.

“Further therapies to protect my patients - especially during complex PCI procedures are needed. At San Raffaele Hospital, we have used PiCSO in elective, as well as acute, high risk PCI procedures and are pleased to see that PiCSO can be applied without significant interruption of our standard workflows and without increasing the risk for the patient,” says Dr. Antonio Colombo, Director of Cardiovascular Interventions at San Raffaele Scientific Institute, Columbus Hospital in Milan, Italy. “Once the PiCSO catheter is placed in the coronary sinus and connected to the PiCSO console, therapy is applied fully automatically so that I can focus on the stenting procedure, knowing that the patient’s heart is protected by PiCSO.”

“The feedback and enthusiasm we received during TCT on our latest achievements with the PiCSO Impulse System are very encouraging and show that PiCSO is addressing a huge, unmet clinical need in an area where most other new therapies have failed to demonstrate clinical benefit or effectiveness,“ says Dr. Werner Braun, former Managing Director at BIOTRONIK and now CEO of Miracor. “In the coming months, we will continue our commercial and clinical strategy in Europe and Asia, as well as our efforts to make this therapy available in the US,” he continues.

Hasil (Bahasa Indonesia) 1:

VIENNA, Austria, Oktober 29, 2015 - Miracor medis sistem GmbH (Miracor) hari ini mengumumkan bahwa selama tahun ini konferensi TCT di San Francisco, PiCSO telah telah disorot dalam beberapa sesi seperti menawarkan harapan baru untuk Cardioprotection selama Percutaneous Coronary intervensi (PCI). TCT (Transcatheter kardiovaskular Therapeutics) adalah mengkhususkan diri dalam intervensi pengobatan kardiovaskular pertemuan pendidikan terbesar di dunia dan diselenggarakan oleh Yayasan penelitian kardiovaskular (CRF) pada 2015 10-16 Oktober di San Francisco, CA, Amerika Serikat.Infark miokard penyelamatan dan kebutuhan cardioprotection untuk pasien dengan infark miokard akut (AMI) pada topik fokus, belum lagi, tahun ini TCT konferensi."Meskipun perbaikan terbaru dalam pengobatan AMI, termasuk disingkat pintu-ke-balon waktu maju farmakologis strategi, kelangsungan hidup telah stabil dan novel strategi yang diperlukan untuk mengurangi ukuran penanganan pasien yang mengalami dan meningkatkan hasil klinis, terutama pada pasien dengan besar ST-segment elevation MI (STEMI)," dinyatakan Dr Gregg W. batu, Profesor kedokteran di Columbia University College dan Direktur Riset kardiovaskular dan pendidikan di New York-Presbyterian Hospital Center untuk intervensi vaskular terapi , selama Simposium pada novel strategi di PCI dengan fokus pada terapi PiCSO. "Dalam beberapa tahun terakhir, banyak pendekatan untuk meningkatkan keberhasilan reperfusi dan infark miokard penyelamatan telah gagal. Muncul data menunjukkan bahwa pengiriman efektif PICSO meningkatkan perfusi miokard dan dapat mengurangi ukuran penanganan pasien yang mengalami STEMI pasien,"lanjutnya.PiCSO is applied during the stenting procedure, directly following flow restoration and increases myocardial perfusion and microcirculation, thereby preventing so-called reperfusion injury, damage to the myocardium caused by the stenting procedure itself.“Further therapies to protect my patients - especially during complex PCI procedures are needed. At San Raffaele Hospital, we have used PiCSO in elective, as well as acute, high risk PCI procedures and are pleased to see that PiCSO can be applied without significant interruption of our standard workflows and without increasing the risk for the patient,” says Dr. Antonio Colombo, Director of Cardiovascular Interventions at San Raffaele Scientific Institute, Columbus Hospital in Milan, Italy. “Once the PiCSO catheter is placed in the coronary sinus and connected to the PiCSO console, therapy is applied fully automatically so that I can focus on the stenting procedure, knowing that the patient’s heart is protected by PiCSO.”“The feedback and enthusiasm we received during TCT on our latest achievements with the PiCSO Impulse System are very encouraging and show that PiCSO is addressing a huge, unmet clinical need in an area where most other new therapies have failed to demonstrate clinical benefit or effectiveness,“ says Dr. Werner Braun, former Managing Director at BIOTRONIK and now CEO of Miracor. “In the coming months, we will continue our commercial and clinical strategy in Europe and Asia, as well as our efforts to make this therapy available in the US,” he continues.